Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT06013111	TitleAn Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors	Phase Phase 1	Date Added 2023-08-28	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05438342	TitleAn Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis	Phase Not Applicable	Date Added 2022-06-29	Location China	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Chemotherapy，checkpoint immunotherapy, targeted therapy	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03692429	TitlealloSHRINK – Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells	Phase Phase 1	Date Added 2018-10-02	Location Florida, United States Belgium	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs CYAD-101, FOLFIRI, FOLFOX	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03935893	TitleAdoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers	Phase Phase 2	Date Added 2019-05-02	Location Pennsylvania, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Fludarabine + Cyclophosphamide combination, Tumor Infiltrating Lymphocytes (TIL)	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03296137	TitleAdoptive Cell Therapy Across Cancer Diagnoses	Phase Phase 1/Phase 2	Date Added 2017-09-28	Location Denmark	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy	Tags MSS/ MMRp
NCT ID NCT03412877	TitleAdministration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	Phase Phase 2	Date Added 2018-01-29	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Aldesleukin, Cyclophosphamide, Fludarabine, Individual Patient TCR-Transduced PBL, Pembrolizumab (Keytruda)	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03190941	TitleAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients	Phase Phase 1, Phase 2	Date Added 2017-06-19	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Anti-KRAS G12V mTCR PBL, Cyclophosphamide, Fludarabine, High-dose Aldesleukin	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03745326	TitleAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients	Phase Phase 1, Phase 2	Date Added 2018-11-19	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03280511	TitleAdjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients	Phase Phase 2	Date Added 2017-09-12	Location Denmark	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs PIPAC	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05382741	TitleAdjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial	Phase Phase 2	Date Added 2022-05-19	Location Italy	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga	Tags MSS/ MMRp

Showing 231 to 240 of 299 entries